Confidence intervals and statistical power of the ‘Validation’ ratio for surrogate or intermediate endpoints

[1]  V De Gruttola,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.

[2]  T. Fleming,et al.  Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.

[3]  S. Dawsey,et al.  Surrogate end points in cancer research: a critique. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[5]  Randy R. Sitter,et al.  On the Accuracy of Fieller Intervals for Binary Response Data , 1993 .

[6]  L S Freedman,et al.  Sample size for studying intermediate endpoints within intervention trails or observational studies. , 1992, American journal of epidemiology.

[7]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[8]  D. A. Williams,et al.  Interval estimation of the median lethal dose. , 1986, Biometrics.

[9]  Nathaniel Schenker,et al.  Qualms about Bootstrap Confidence Intervals , 1985 .

[10]  J. Mullahy,et al.  Valuing health care: Statistical issues in cost–effectiveness analyses , 1995 .

[11]  F. Sloan.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .

[12]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[13]  C. Cox.  Fieller's theorem, the likelihood and the delta method , 1990 .

[14]  E. C. Fieller.  The Biological Standardization of Insulin , 1940 .